JP2010509204A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509204A5 JP2010509204A5 JP2009535151A JP2009535151A JP2010509204A5 JP 2010509204 A5 JP2010509204 A5 JP 2010509204A5 JP 2009535151 A JP2009535151 A JP 2009535151A JP 2009535151 A JP2009535151 A JP 2009535151A JP 2010509204 A5 JP2010509204 A5 JP 2010509204A5
- Authority
- JP
- Japan
- Prior art keywords
- omega
- lipid composition
- eicosapentaen
- prodrug
- docosahexaen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims 106
- 150000002632 lipids Chemical class 0.000 claims 99
- 239000000651 prodrug Substances 0.000 claims 68
- 229940002612 prodrug Drugs 0.000 claims 68
- 150000001298 alcohols Chemical class 0.000 claims 48
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 41
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 13
- 235000015872 dietary supplement Nutrition 0.000 claims 12
- 238000004519 manufacturing process Methods 0.000 claims 12
- 125000003342 alkenyl group Chemical group 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- 150000002148 esters Chemical class 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 239000002253 acid Substances 0.000 claims 4
- 150000007513 acids Chemical class 0.000 claims 4
- -1 omega-3 fatty acid ester Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000004475 Arginine Substances 0.000 claims 3
- 229920001661 Chitosan Polymers 0.000 claims 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims 3
- 229910010082 LiAlH Inorganic materials 0.000 claims 3
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 239000003153 chemical reaction reagent Substances 0.000 claims 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims 3
- 229960003194 meglumine Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 2
- 229910052782 aluminium Inorganic materials 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 229910052796 boron Inorganic materials 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 150000004678 hydrides Chemical class 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 2
- 239000002994 raw material Substances 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010014486 Elevated triglycerides Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000001258 dyslipidemic effect Effects 0.000 claims 1
- 235000019197 fats Nutrition 0.000 claims 1
- 235000021323 fish oil Nutrition 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- ZYYXPAPDNCOHOS-UHFFFAOYSA-N icosa-1,3,5,7,9-pentaen-1-ol Chemical compound CCCCCCCCCCC=CC=CC=CC=CC=CO ZYYXPAPDNCOHOS-UHFFFAOYSA-N 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 229940106134 krill oil Drugs 0.000 claims 1
- 239000012280 lithium aluminium hydride Substances 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 235000019198 oils Nutrition 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 229930003799 tocopherol Natural products 0.000 claims 1
- 235000010384 tocopherol Nutrition 0.000 claims 1
- 239000011732 tocopherol Substances 0.000 claims 1
- 125000002640 tocopherol group Chemical group 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
- MBBZMMPHUWSWHV-UHFFFAOYSA-N CNCC(C(C(C(CO)O)O)O)O Chemical compound CNCC(C(C(C(CO)O)O)O)O MBBZMMPHUWSWHV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85626906P | 2006-11-03 | 2006-11-03 | |
| US85626706P | 2006-11-03 | 2006-11-03 | |
| US85626806P | 2006-11-03 | 2006-11-03 | |
| SE0602352 | 2006-11-03 | ||
| PCT/IB2007/004590 WO2008139261A2 (en) | 2006-11-03 | 2007-11-02 | Omega-3 lipid compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010509204A JP2010509204A (ja) | 2010-03-25 |
| JP2010509204A5 true JP2010509204A5 (enExample) | 2010-12-24 |
Family
ID=39876685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009535151A Pending JP2010509204A (ja) | 2006-11-03 | 2007-11-02 | 脂肪酸アルコール |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100266681A1 (enExample) |
| JP (1) | JP2010509204A (enExample) |
| KR (1) | KR20090077081A (enExample) |
| CN (1) | CN101646426A (enExample) |
| BR (1) | BRPI0718393A2 (enExample) |
| CA (1) | CA2667153A1 (enExample) |
| MX (1) | MX2009004339A (enExample) |
| NO (1) | NO20092131L (enExample) |
| RU (1) | RU2009121007A (enExample) |
| WO (1) | WO2008139261A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009134147A1 (en) * | 2008-05-02 | 2009-11-05 | Pronova Biopharma Norge As | Lipid compositions containing derivatives of epa and dha an their use thereof |
| GB201009368D0 (en) * | 2010-06-04 | 2010-07-21 | Sana Pharma As | Dietary formulations |
| WO2012029898A1 (ja) * | 2010-09-01 | 2012-03-08 | 日本水産株式会社 | アルコール性障害緩和剤 |
| BR112014031086A2 (pt) * | 2012-06-11 | 2017-06-27 | Cleveland Clinic Found | tratamento e prevenção de doenças cardiovasculares e trombose |
| CN102860506A (zh) * | 2012-08-08 | 2013-01-09 | 辽宁省大连海洋渔业集团公司 | 磷虾油微囊粉及其制备方法 |
| US9365482B2 (en) * | 2013-02-28 | 2016-06-14 | Pronova Biopharma Norge As | Methods of preparing fatty acid derivatives |
| EP2826384A1 (de) | 2013-07-16 | 2015-01-21 | Evonik Industries AG | Verfahren zur Trocknung von Biomasse |
| WO2016050559A1 (de) | 2014-10-02 | 2016-04-07 | Evonik Degussa Gmbh | VERFAHREN ZUR HERSTELLUNG EINES PUFAs ENTHALTENDEN FUTTERMITTELS DURCH EXTRUSION EINER PUFAs ENTHALTENDEN BIOMASSE |
| BR112017006833B1 (pt) | 2014-10-02 | 2022-09-13 | Evonik Operations Gmbh | Alimento para animais contendo ácido graxo poli-insaturado e processo para produzir o mesmo |
| CA2958463C (en) | 2014-10-02 | 2022-05-03 | Evonik Industries Ag | Method for raising animals |
| ES2870093T3 (es) | 2014-10-02 | 2021-10-26 | Evonik Operations Gmbh | Biomasa que contiene PUFA con estabilidad celular elevada y su empleo para la producción de piensos |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01207224A (ja) * | 1988-02-10 | 1989-08-21 | Nonogawa Shoji:Kk | 頭髪用化粧料及び養毛剤 |
| GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| DE60132508T2 (de) * | 2000-01-31 | 2008-04-30 | Härting S.A. | Zusammensetzungen enthaltend Phytosterol- und Policosanolester von Fettsäuren zur Herabsetzung des Cholesterol- und Triglyceridspiegels |
| ATE271406T1 (de) * | 2000-09-21 | 2004-08-15 | Nutrition 21 Inc | Chrom enthaltende zusammensetzung zur behandlung von diabetes, zur verbesserung der insulinsensitivität und zur reduktion von hyperglykämie, hypercholesterolämie und des körperfettanteils |
| DK1997498T3 (da) * | 2001-06-18 | 2012-07-30 | Neptune Technologies & Bioressources Inc | Krillekstrakter til forebyggelse og/eller behandling af kardiovaskulære sygdomme |
| ITMI20012384A1 (it) * | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
| CN1665496B (zh) * | 2002-05-03 | 2010-05-05 | 派普生物保健品公司 | Epa和dha在制备二级预防神经性疾患的药物中的用途 |
| AU2003252324A1 (en) * | 2002-08-07 | 2004-03-11 | Kao Corporation | Fat composition |
| US8017651B2 (en) * | 2002-11-22 | 2011-09-13 | Bionexus, Ltd. | Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia |
| WO2004078166A2 (en) * | 2003-03-05 | 2004-09-16 | Solvay Pharmaceuticals Gmbh | Use of omega-3-fatty acids in the treatment of diabetic patients |
| SE0303513D0 (sv) * | 2003-12-19 | 2003-12-19 | Pronova Biocare As | Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof |
-
2007
- 2007-11-02 CA CA002667153A patent/CA2667153A1/en not_active Abandoned
- 2007-11-02 MX MX2009004339A patent/MX2009004339A/es not_active Application Discontinuation
- 2007-11-02 CN CN200780040625A patent/CN101646426A/zh active Pending
- 2007-11-02 RU RU2009121007/04A patent/RU2009121007A/ru not_active Application Discontinuation
- 2007-11-02 JP JP2009535151A patent/JP2010509204A/ja active Pending
- 2007-11-02 WO PCT/IB2007/004590 patent/WO2008139261A2/en not_active Ceased
- 2007-11-02 KR KR1020097011471A patent/KR20090077081A/ko not_active Ceased
- 2007-11-02 BR BRPI0718393-3A patent/BRPI0718393A2/pt not_active IP Right Cessation
- 2007-11-02 US US12/447,971 patent/US20100266681A1/en not_active Abandoned
-
2009
- 2009-06-02 NO NO20092131A patent/NO20092131L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010509204A5 (enExample) | ||
| RU2009121007A (ru) | Жирные спирты | |
| RU2509071C2 (ru) | Новые липидные соединения | |
| US6555700B1 (en) | 1,3-propane diol esters and ethers and methods for their use in drug delivery | |
| TW522013B (en) | Pharmaceutical composition comprising L-carnitine or an alkanoyl L-carnitine in combination with a polyunsaturated fatty acid of the omega-3 series for the prevention and the treatment of lipid metabolism disorders | |
| JP6106158B2 (ja) | 酸化的網膜疾患 | |
| ES2733353T3 (es) | Compuestos lípidos para uso en productos cosméticos, como suplemento alimenticio o como un medicamento | |
| JP5552314B2 (ja) | 新規脂質化合物 | |
| JP2011528350A5 (enExample) | ||
| JP2009526033A (ja) | オメガ３ | |
| JP2008540394A5 (enExample) | ||
| EP2094640A1 (en) | Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar). | |
| JP2011503057A5 (enExample) | ||
| JP2015518862A (ja) | クルクミンを含有する改善された複合体および組成物 | |
| JP2775627B2 (ja) | 治療用組成物 | |
| JPWO2019208392A1 (ja) | 新規プラズマローゲン誘導体 | |
| AU2019204443A1 (en) | Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances | |
| JPH0761954B2 (ja) | コレステロール低下または上昇抑制剤 | |
| JP2018510206A5 (enExample) | ||
| JP2007524344A (ja) | ヒドロキシオレイン酸及び関連化合物の機能性食品添加物としての使用 | |
| EP4126057A1 (en) | Composition having improved voluntary acceptance | |
| USRE40546E1 (en) | 1,3-Propane diol esters and ethers and methods for their use in drug delivery | |
| JPS6049747A (ja) | リン脂質組成物 | |
| JP2013184939A (ja) | 体重増加抑制剤 | |
| JP2001288079A (ja) | 特異的殺癌細胞剤及びこれを配合してなる組成物 |